Changes in serum cytokine levels in active tuberculosis with treatment

被引:61
作者
Deveci, F [1 ]
Akbulut, HH
Turgut, T
Muz, MH
机构
[1] Firat Univ, Fac Med, Firat Med Ctr, Dept Chest Dis, TR-23119 Elazig, Turkey
[2] Firat Univ, Dept Immunol, Fac Med, TR-23119 Elazig, Turkey
关键词
D O I
10.1155/MI.2005.256
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
It has been reported that IFN-(gamma), TNF-alpha, and IL-12 stimulate, and that IL-10, TGF-beta, and IL-4 suppress the protective immune response against tuberculosis. We aim to evaluate changes in the serum levels of pro and antiinflammatory cytokines in active pulmonary tuberculosis (APTB) and the possible effects of treatment on these changes. Serum IL-12p40, IL-4, IL-10, TNF-alpha, IFN-gamma, and TGF-beta 1 levels were determined in 20 APTB cases (group 1) before and 2, 4, and 6 months after therapy. The same parameters were also determined in 9 inactive pulmonary tuberculosis (IPTB) cases (group 2) and 9 healthy controls (HC, group 3). Before treatment, the mean serum IFN-gamma, TNF-alpha, and IL-10 levels in group I were statistically higher than those in group 2 (P =.001, P =.024, P =.016, resp) or group 3 (P =.003, P =.002, P =. 0 11, resp). The levels in group I decreased significantly after treatment (P =.001 for IFN-gamma, P =.004 for TNF-alpha, P =.000 for IL-10). The serum levels of IL-12p40 were significantly higher in group I than in group 3 (P =.012) and decreased insignificantly after treatment. There was no difference in serum IL-4 and TGF-beta 1 levels among the groups (P >.05). Because the serum IL-12p40, IL-10, TNF-alpha, and IFN-gamma levels were high in APTB, we believe that these cytokines have important roles in the immune response to Mycobacterium tuberculosis (M tuberculosis). These parameters could be used in follow-up as indicators of the success of APTB therapy.
引用
收藏
页码:256 / 262
页数:7
相关论文
共 52 条
[1]  
Ameglio F, 2005, INT J TUBERC LUNG D, V9, P98
[2]   CYTOKINE PRODUCTION AT THE SITE OF DISEASE IN HUMAN TUBERCULOSIS [J].
BARNES, PF ;
LU, SZ ;
ABRAMS, JS ;
WANG, E ;
YAMAMURA, M ;
MODLIN, RL .
INFECTION AND IMMUNITY, 1993, 61 (08) :3482-3489
[3]  
BARNES PF, 1992, J IMMUNOL, V149, P541
[4]  
BASS JB, 1990, AM REV RESPIR DIS, V142, P725
[5]   Selective increase in plasma tumor necrosis factor-α and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis [J].
Bekker, LG ;
Maartens, G ;
Steyn, L ;
Kaplan, G .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (02) :580-584
[6]   Change in serum concentrations of interleukin-2 and interferon-γ during treatment of tuberculosis [J].
Berktas, M ;
Guducuoglu, H ;
Bozkurt, H ;
Onbasi, KT ;
Kurtoglu, MG ;
Andic, S .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2004, 32 (03) :324-330
[7]  
BERMUDEZ LEM, 1988, J IMMUNOL, V140, P3006
[8]  
BOGDAN C, 1992, J BIOL CHEM, V267, P23301
[9]   Down-modulation of lung immune responses by interleukin-10 and transforming growth factor β (TGF-β) and analysis of TGF-β receptors I and II in active tuberculosis [J].
Bonecini-Almeida, MG ;
Ho, JL ;
Boéchat, N ;
Huard, RC ;
Chitale, S ;
Doo, H ;
Geng, JY ;
Rego, L ;
Lazzarini, LCO ;
Kritski, AL ;
Johnson, WD ;
McCaffrey, TA ;
Silva, JRLE .
INFECTION AND IMMUNITY, 2004, 72 (05) :2628-2634
[10]   Human immunity to M-tuberculosis:: T cell subsets and antigen processing [J].
Boom, WH ;
Canaday, DH ;
Fulton, SA ;
Gehring, AJ ;
Rojas, RE ;
Torres, M .
TUBERCULOSIS, 2003, 83 (1-3) :98-106